NCT04471818 (KODIAC) is a Phase 1, PHASE2 clinical trial of Ketamine in Major Depressive Disorder, sponsored by Instituto Nacional de Cancerologia de Mexico.

Who is sponsoring NCT04471818?

NCT04471818 is sponsored by Instituto Nacional de Cancerologia de Mexico.

What drugs are being tested in NCT04471818?

Interventions in NCT04471818: Ketamine, Placebo.

What condition does NCT04471818 study?

NCT04471818 studies Major Depressive Disorder, Advanced Cancer.

Is NCT04471818 still recruiting?

NCT04471818 is currently completed. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT04471818: KODIAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketamine or Placebo in Patients With Major Depression and Advanced Cancer

Completed Phase 1, PHASE2 Last updated 28 September 2023

What this trial tests

Phase 1, PHASE2 trial testing Ketamine in Major Depressive Disorder in 19 participants. Completed in 30 July 2023.

Timeline

19 September 2019

Primary endpoint
1 June 2023

30 July 2023

Quick facts

Lead sponsor	Instituto Nacional de Cancerologia de Mexico
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	19
Start date	19 September 2019
Primary completion	1 June 2023
Estimated completion	30 July 2023
Sites	1 location across Mexico

Drugs / interventions tested

Ketamine (ketamine) — full drug profile →
Placebo

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →
Advanced Cancer — all drugs for Advanced Cancer →

Sponsor

Instituto Nacional de Cancerologia de Mexico — full company profile →

Who can join

Adults 18 to 65, any sex, with Major Depressive Disorder or Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Major depression (MD) is a psychiatric disorder characterized by a persistent feeling of sadness, anhedonia or a decreased perception of pleasurable experiences, as well as appetite alterations and weight variations, sleep disorders, altered psychomotor skills, fatigue, guilt, decreased self-worth, suicidal thoughts and difficulty concentrating in a task (1). MD is a frequent complication in patients who are diagnosed with advanced cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care: A systematic review.
Barbosa MG, Garcia GT, Sarin LM, Jackowski AP. · · 2023 · cited 5× · PMID 36574497 · DOI 10.47626/1516-4446-2022-2876

Verify or expand the search:

Other trials of Ketamine

Trials testing the same drug.

NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
NCT06963294 — Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty · NA · not yet recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg · NA · not yet recruiting
NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other Instituto Nacional de Cancerologia de Mexico trials

Trials by the same sponsor.

NCT06422533 — Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients · NA · recruiting
NCT06477302 — Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer · recruiting
NCT06090747 — Improving Lifestyle Behavior by "Joven, Fuerte y Saludable" Multidisciplinary Program. · NA · recruiting
NCT06238882 — Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. · NA · recruiting
NCT06883409 — Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04471818 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Nacional de Cancerologia de Mexico
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04471818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing